Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Drugs
Erschienen in:

27.02.2024 | AdisInsight Report

Berdazimer Topical Gel, 10.3%: First Approval

verfasst von: Susan J. Keam

Erschienen in: Drugs | Ausgabe 3/2024

Einloggen, um Zugang zu erhalten

Abstract

Berdazimer topical gel, 10.3% (ZELSUVMI™) is a nitric oxide (NO) releasing topical gel developed by Novan Inc. (a Ligand Pharmaceuticals company) for the treatment of molluscum contagiosum (MC). Novan has used their proprietary NO-based technology platform (NITRICIL™), which stores gaseous NO species on large polymers, in the development of berdazimer topical gel, 10.3%. In January 2024, berdazimer topical gel, 10.3% was approved for the topical treatment of MC in adult and paediatric patients 1 year of age and older in the USA. This article summarizes the milestones in the development of berdazimer topical gel, 10.3% leading to this first approval for the treatment of MC.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Eichenfield L, Hebert A, Mancini A, et al. Therapeutic approaches and special considerations for treating molluscum contagiosum. J Drugs Dermatol. 2021;20(11):1185–90.CrossRefPubMed
2.
Lacarrubba F, Micali G, Trecarichi AC, et al. New developing treatments for molluscum contagiosum. Dermatol Ther (Heidelb). 2022;12(12):2669–78.CrossRefPubMedPubMedCentral
3.
Olsen JR, Gallacher J, Finlay AY, et al. Time to resolution and effect on quality of life of molluscum contagiosum in children in the UK: a prospective community cohort study. Lancet Infect Dis. 2015;15(2):190–5.CrossRefPubMed
4.
Oza VS. Molluscum contagiosum therapeutics—new options may be around the corner. JAMA Dermatol. 2022;158(8):863–4.CrossRefPubMed
5.
6.
Sugarman JL, Hebert A, Browning JC, et al. Berdazimer gel for molluscum contagiosum: an integrated analysis of 3 randomized controlled trials. J Am Acad Dermatol. 2023;00(00):1–10.
7.
Maeda-Chubachi T, Hebert D, Messersmith E, Siegfried EC. SB206, a nitric oxide-releasing topical medication, induces the beginning of the end sign and molluscum clearance. JID Innov. 2021;1(3):1–8.CrossRef
8.
Del Rosso JQ, Kircik J. Spotlight on the use of nitric oxide in dermatology: What is it? What does it do? Can it become an important addition to the therapeutic armamentarium for skin disease? J Drugs Dermatol. 2017;16(1 Suppl):s4–10.PubMed
9.
Banerjee NS, Moore DW, Wang HK, et al. NVN1000, a novel nitric oxide-releasing compound, inhibits HPV-18 virus production by interfering with E6 and E7 oncoprotein functions. Antiviral Res. 2019;170(00):1–9.
10.
Cartwright M, Enloe C, Stripling S, Maeda-Chubachi T. Pharmacokinetic profile, safety, and tolerability of topical berdazimer gel, 10.3% in patients with molluscum contagiosum. J Drugs Dermatol. 2022;21(10):1104–10.CrossRefPubMed
11.
12.
13.
14.
15.
16.
17.
Browning JC, Enloe C, Cartwright M, et al. Efficacy and safety of topical nitric oxide-releasing berdazimer gel in patients with molluscum contagiosum: a phase 3 randomized clinical trial. JAMA Dermatol. 2022;158(8):871–8.PubMedPubMedCentral
18.
Ward BM, Riccio DA, Cartwright M, Maeda-Chubachi T. The antiviral effect of berdazimer sodium on molluscum contagiosum virus using a novel in vitro methodology. Viruses. 2023;15(12):1–11.CrossRef
19.
Stripling S, Hebert A, Enloe C, et al. Clinical development program of novel topical nitric oxide releasing medication berdazimer gel 10.3% for the once-daily treatment of molluscum contagiosum [abstract no. and poster]. In: SCALE 2022. 2022.
20.
21.
Novan Inc. A phase 3 randomized parallel group study comparing the efficacy & safety of SB206 & vehicle gel in the treatment of MC (B-SIMPLE1). 2022. https://​clinicaltrials.​gov/​. Accessed 1 Feb 2024.
22.
Hebert AA, Siegfried EC, Durham T, et al. Efficacy and tolerability of an investigational nitric oxide-releasing topical gel in patients with molluscum contagiosum: a randomized clinical trial. J Am Acad Dermatol. 2020;82(4):887–94.CrossRefPubMed
23.
Ligand Pharmaceuticals Inc. U.S. Food and Drug Administration approves ZELSUVMI™ as a first-in-class medication for the treatment of molluscum contagiosum [media release]. 5 Jan 2024. https://​investor.​ligand.​com/​.
Metadaten
Titel
Berdazimer Topical Gel, 10.3%: First Approval
verfasst von
Susan J. Keam
Publikationsdatum
27.02.2024
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 3/2024
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-024-02012-9

Weitere Artikel der Ausgabe 3/2024

Adult-Onset Still’s Disease (AOSD): Advances in Understanding Pathophysiology, Genetics and Emerging Treatment Options

  • Open Access
  • Review Article

Vonoprazan: A Review in Helicobacter pylori Infection

  • Open Access
  • Adis Drug Evaluation

Capivasertib: First Approval

  • AdisInsight Report

Correction: Lumasiran: A Review in Primary Hyperoxaluria Type 1

  • Open Access
  • Correction

Correction: Zilucoplan: First Approval

  • Open Access
  • Correction

SER-109 (VOWST™): A Review in the Prevention of Recurrent Clostridioides difficile Infection

  • Adis Drug Evaluation